In an effort to improve on the efficiency of running endocrine function, hormones, toxicology, abused drugs, and immunosuppressants tests, Abbott introduced the TDxFLx in 1991 which incorporates random access capabilities. Although the therapeutic drug monitoring market has undergone several important changes in the past 20 years, Abbott continues to lead the way.